Medizone International Selects Cogmedix as Medical Device Manufacturing Services Provider

Worcester, Massachusetts, July 19, 2016: Cogmedix, a wholly owned subsidiary of Coghlin Companies Inc., established in 1885, is proud to announce that Medizone International, Inc., (OTCQB: MZEI) has selected Cogmedix as their turnkey medical device manufacturing services provider for the AsepticSure® Generation III hospital disinfection system.

This partnership is the culmination of months of collaboration. Medizone Chairman and CEO, Edwin Marshall, was elated with this milestone and stated, “In Cogmedix we have contracted with a seasoned FDA medical device manufacturer with a depth of supply chain resources and the expertise to ensure the highest quality product is delivered, while also carefully controlling manufacturing costs. We’re convinced Cogmedix will enable us to meet significant increases in product demand as we enter the US market and also serve manufacturing requirements for international markets as AsepticSure® puts an end to environmentally caused hospital-acquired infection worldwide.”

Cogmedix Executive Vice President and General Manager, Matt Giza, shared Marshall’s enthusiasm. “Cogmedix is very excited to be a part of the impact AsepticSure® will have across the globe. The need for this technology extends well beyond hospitals. We are thrilled to be a key part of its commercialization.”

Units manufactured by Cogmedix will meet the growing demand for greater than 6-log (>99.9999%) disinfection in hospital rooms and other critical infrastructure across the globe.

The AsepticSure® process demonstrates a previously unobtainable level of hospital room disinfection within normal workflows while demonstrating immediate and dramatic reductions in new hospital- associated infection rates. AsepticSure® is the only hospital disinfection system that can guarantee a kill of infective pathogens, both bacterial and viral, of greater than 6-log (>99.9999%) throughout the entire room, and can independently verify it using the same FDA recommended testing products used to confirm surgical instrument sterilization in autoclaves.

About Cogmedix

Screen Shot 2016-07-19 at 9.31.47 AMCogmedix is a team of talented Caring Associates that brings OEM medical technology to life. Providing turnkey medical device manufacturing services to a broad range of medical and dental OEMs, Cogmedix delivers high-quality products to market with compliance, competence, and commitment. Cogmedix provides a high level of flexibility in product launch and demand management and aligns itself with innovative companies that maintain similarly high standards in honesty and integrity. Cogmedix is a subsidiary of Coghlin Companies, Inc., a privately held concept-to-commercialization firm spanning four generations. Visit Cogmedix and sign up for the e-Newsletter at www.cogmedix.com.

About Medizone

Medizone International, Inc. (OTCQB: MZEI) is a provider of patented low dose ozone based disinfection systems. The AsepticSure® hospital disinfection system, which is used in disinfecting hospital isolation rooms, surgical suites, emergency rooms, and intensive care units, as well as other enclosed spaces, such as gym locker rooms, laboratories, and veterinary clinics, establishes a new gold standard in disinfection technology by completely eliminating infective pathogens from the entire space treated. By eliminating the reservoir of infective pathogen, the treated space then remains safe until another infective pathogen is reintroduced from the outside. This breaks the chain of reinfection that hospitals globally continue to suffer through today. AsepticSure greatly reduces operational costs through the savings associated with treating far fewer HAIs. Medizone was founded in New York in 1986 and is now based in Sausalito, California. www.medizoneint.com

AsepticSure’s South American Distributor Places Order

San Francisco, California, June 20, 2016: Medizone International, Inc. (OTCQB: MZEI). GYD S.A., Medizone’s exclusive distributor for our AsepticSure® hospital disinfection system in Chile, Brazil, Colombia and Peru, intends to offer both a service model and sales model for AsepticSure distribution. They are leading the regulatory approval process in their Territory. Exclusive distribution rights will be expanded to other countries in South America on a country-by-country basis as GYD S.A. achieves regulatory approvals and establishes channels of distribution.

With regulatory approval progressing, GYD S.A. has placed an initial order for the first three Generation III AsepticSure systems. Delivery is scheduled for early July.

While the roll out of AsepticSure distribution throughout South America will be gradual, the principals of GYD S.A. have been successful twice before using the same business model in establishing distribution channels throughout the continent. Given the acute need to address major hospital based infection issues on the continent, including evidence of super bugs in Rio with the up-coming Olympic Games, the ability to greatly reduce these infection threats in the health care community is gaining attention. Medizone believes GYD S.A.’s proven business model will be successful again.

Only AsepticSure disinfection technology achieves a greater than 6-log (> 99.9999%) kill of all infective pathogensviral or bacterialthroughout the entire room. That is the same FDA standard of disinfection used to sterilize medical instruments in an autoclave. Once a room is disinfected with AsepticSure’s ‘green’ technology, it will remain safe until a new pathogen is introduced from the outside. Medizone has proven that unless 100% of infective pathogens are eliminated from the disinfected space, regrowth will occur and new infections become likely. No other disinfection technology has proven capable of eliminating the source of environmentally caused infections completely; AsepticSure does so with every room cleaning.

This Press Release may contain certain forward looking statements that could involve substantial risks and uncertainties, including, but not limited to, the results of ongoing clinical studies, economic conditions, product and technology development, production efficiencies, product demand, competitive products, competitive environment, successful testing and government regulatory issues. Additional risks are identified in the company’s filings made with the Securities and Exchange Commission.

For press information on Medizone International, please contact:

John Pentony, Investor and Media Relations
Medizone International, Inc.
T: 01 415 331-0202
E: j.pentony@medizoneint.com

For more information, visit:
http://www.medizoneint.com
Email: operations@medizoneint.com

Medizone International, Inc. (OTCQB: MZEI)

4000 Bridgeway, Suite 401
Sausalito, CA 94965

Telephone: 415-331-0303

Email: operations@medizoneint.com

Media and Investor Relations:

John Pentony

Medizone International, Inc.

Telephone: (415) 331-0202

Email: j.pentony@medizoneint.com

Social Media


Twitter:


https://twitter.com/asepticsure

CONTACT:

Medizone International, Inc. (OTCQB: MZEI)
4000 Bridgeway, Suite 401
Sausalito, CA 94965

Telephone: 415-331-0303

Email: operations@medizoneint.com

INVESTOR & MEDIA RELATIONS:

John Pentony
Medizone International, Inc.

Telephone: (415) 331-0202E:

Email: j.pentony@medizoneint.com

SOCIAL MEDIA:

Medizone International on Twitter:

https://twitter.com/asepticsure